1. Medtech Insight
  2. >>Archive

Genetic Biomarkers Offer New Hope In Identifying Prostate Cancer

Although physicians still struggle with the best ways to treat patients suspected of having prostate cancer, a new group of genetic-based tests could provide new tools that will help improve diagnostic accuracy. These new biomarkers offer hope in reducing the number of patients who receive unnecessary treatment for cancers that are not actually present in their bodies and for those cancers not aggressive enough to cause harm.

While over-treating still remains a major problem in addressing prostate cancer, science continues to improve the task of identifying which patients actually need treatment as well as clarifying what treatments are most appropriate. The prostate-specific antigen (PSA) screening test still remains a stable tool physicians use to help detect prostate cancer, but an array of new biomarkers designed for various stages of prostate cancer have made their way into the market, which has proven to be fertile ground for young companies. (SeeAlso see "Prostate Cancer: Dissatisfaction With Current Diagnostics Drives Interest In Innovation" - Medtech Insight, 21 April, 2015..) As with most new products in health care, the key to successful adoption is not only a positive effect on patient outcomes, but also a proven ability to reduce costs, and without those elements payer reimbursement can be difficult to obtain.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Precision Neuroscience’s FDA Clearance For Core Component Of Brain Implant Expected to Accelerate R&D

 
• By Marion Webb

Precision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

J&J Survey: Clinician Burnout And Aging Populations Drive Demand For AI And Robotics In Future Health Care

 
• By Shubham Singh

According to a survey of health care professionals by J&J, over 45% of surveyed respondents reported experiencing symptoms of burnout, including emotional exhaustion and reduced sense of personal accomplishment. This affects not just clinicians, but also the quality and safety of care they deliver. Most clinicians (72%) say that data and technology could significantly help alleviate this burden.